A fresh era of earnings growth may be on the horizon.

The biotech has been on a tear lately.

Moderna (MRNA) drew fresh attention after appointing experienced financial executive Michael McDonnell to its Board and Audit ...

Valued at a market cap of $23.7 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing messenger RNA ...

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

French pharmaceutical company Sanofi has filed lawsuits against Pfizer and Moderna, claiming the companies used patented ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In a ...

Moderna has countered a patent-infringement lawsuit brought by biotech company CureVac in Delaware federal court over its ...